REGENXBIO Inc.
5.61xPrice / book
Market cap
$576.30M
Tangible equity (USD)
—
Price / tangible book
—
Price / book
5.61x
Net income / ending equity
-188.7%
Net income / ending assets
-42.8%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $576.30M · View financials
Snapshot Sep 9, 2026, 4:00 PM ET
FY 2025 · View financials
Decision snapshot: RGNX stock price vs BAC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BAC's multiple
Needs BAC P/B.
Implied fair value · at RGNX's multiple
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
$576.30M
Tangible equity (USD)
—
Price / tangible book
—
Price / book
5.61x
Net income / ending equity
-188.7%
Net income / ending assets
-42.8%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity (USD)
$232.42B
Price / tangible book
—
Price / book
—
Net income / ending equity
10.1%
Net income / ending assets
0.9%
Efficiency ratio
61.7%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REGENXBIO Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
BofA Finance LLC · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Sarepta Therapeutics, Inc.
RGNX vs SRPT
Intellia Therapeutics, Inc.
RGNX vs NTLA
JPMorgan Chase & Co.
RGNX vs JPM
Citigroup Inc.
RGNX vs C
Wells Fargo & Company
RGNX vs WFC
The Goldman Sachs Group, Inc.
RGNX vs GS
Morgan Stanley
RGNX vs MS
US BANCORP \DE\
RGNX vs USB
PNC FINANCIAL SERVICES GROUP, INC.
RGNX vs PNC
TRUIST FINANCIAL CORP
RGNX vs TFC
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.